RecruitingNot ApplicableNCT06034327
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
Sponsor
SightGlass Vision, Inc.
Enrollment
150 participants
Start Date
Sep 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.
Eligibility
Min Age: 6 YearsMax Age: 8 Years
Inclusion Criteria9
- Children 6 - 8 years of age (inclusive) at time of informed consent/assent;
- Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye;
- Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye;
- Best corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye;
- The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D;
- Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);
- Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit;
- Willingness to participate in the trial for 24 months without contact lens wear;
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.
Exclusion Criteria9
- Subject has previously or currently wears contact lenses (greater than 1-month usage);
- Current or prior use of bifocals, progressive addition spectacle lenses
- Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology);
- Amblyopia in either eye;
- Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction;
- Any ocular or systemic conditions that could influence refractive development or status \[e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)\];
- Known allergy to proparacaine, tetracaine, or tropicamide;
- Participation in any investigational clinical study within 30 days of the Baseline visit;
- Subject's sibling or other household member is already enrolled in this trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICESingle vision, impact-resistant spectacle lenses; Test Arm
Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
DEVICESingle vision, impact-resistant spectacle lenses; Control Arm
Single vision, impact-resistant spectacle lenses
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06034327
Related Trials
Visual and Postural Behavior in Myopic and Non-Myopic Teenagers
NCT074401341 location
Comparison of Myopic Small Incision Lenticule Extraction (SMILE) With VISUMAX 500 Versus VISUMAX 800 Platforms
NCT075052641 location
Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K
NCT062789741 location
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
NCT0702882711 locations
Comfort and Vision With TOTAL30 Multifocal Lenses
NCT072849661 location